Jan 28, 2025, 17:23
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on X:
“Today, at GI ASCO, I had the privilege of presenting the results of R Phase 2 study of BOT +/- BAL in chemoresistant MSS CRC – an area in dire need of treatment options. BOT75/BAL240 ORR 19%, DCR 55%. BAL value confirmed. Majority study responses ongoing. Durable responses matter.”
More posts featuring Marwan Fakih.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 28, 2025, 17:24
Jan 28, 2025, 17:18